Acute Ischemic Stroke - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 131 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acute Ischemic Stroke - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Acute Ischemic Stroke - Pipeline Review, H1 2016', provides an overview of the Acute Ischemic Stroke pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke
- The report reviews pipeline therapeutics for Acute Ischemic Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Acute Ischemic Stroke therapeutics and enlists all their major and minor projects
- The report assesses Acute Ischemic Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Acute Ischemic Stroke

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Ischemic Stroke Overview 9
Therapeutics Development 10
Pipeline Products for Acute Ischemic Stroke - Overview 10
Acute Ischemic Stroke - Therapeutics under Development by Companies 11
Acute Ischemic Stroke - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Acute Ischemic Stroke - Products under Development by Companies 16
Acute Ischemic Stroke - Companies Involved in Therapeutics Development 18
AB Science SA 18
AstraZeneca Plc 19
Biogen, Inc. 20
D-Pharm Ltd. 21
Daiichi Sankyo Company, Limited 22
DiaMedica Inc. 23
Digna Biotech, S.L. 24
Glucox Biotech AB 25
Grifols, S.A. 26
Lumosa Therapeutics Co., Ltd. 27
Mitsubishi Tanabe Pharma Corporation 28
Pharmicell Co., Ltd. 29
PhytoHealth Corporation 30
Remedy Pharmaceuticals, Inc. 31
Saneron CCEL Therapeutics, Inc. 32
Simcere Pharmaceutical Group 33
Stemedica Cell Technologies, Inc. 34
Acute Ischemic Stroke - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
3K3A-APC - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ApTLR-4FT - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Cellgram-IS - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DB-017 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
DM-199 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
DS-1040 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
glyburide - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
HBI-002 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
HBN-1 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
LT-3001 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
masitinib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MP-124 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
natalizumab - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PHN-014 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Rejuveinix - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SIM-071201 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
TAL-0500018 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
THR-18 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
ticagrelor - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
TMS-007 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Acute Ischemic Stroke - Recent Pipeline Updates 87
Acute Ischemic Stroke - Dormant Projects 117
Acute Ischemic Stroke - Discontinued Products 119
Acute Ischemic Stroke - Product Development Milestones 121
Featured News & Press Releases 121
Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia 121
Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial 121
Nov 04, 2015: DiaMedica Provides Corporate Update 122
Oct 09, 2015: Remedy Pharmaceuticals' Drug CIRARA

List of Tables

Number of Products under Development for Acute Ischemic Stroke, H1 2016 10
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 (Contd..1) 17
Acute Ischemic Stroke - Pipeline by AB Science SA, H1 2016 18
Acute Ischemic Stroke - Pipeline by AstraZeneca Plc, H1 2016 19
Acute Ischemic Stroke - Pipeline by Biogen, Inc., H1 2016 20
Acute Ischemic Stroke - Pipeline by D-Pharm Ltd., H1 2016 21
Acute Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 22
Acute Ischemic Stroke - Pipeline by DiaMedica Inc., H1 2016 23
Acute Ischemic Stroke - Pipeline by Digna Biotech, S.L., H1 2016 24
Acute Ischemic Stroke - Pipeline by Glucox Biotech AB, H1 2016 25
Acute Ischemic Stroke - Pipeline by Grifols, S.A., H1 2016 26
Acute Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H1 2016 27
Acute Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 28
Acute Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H1 2016 29
Acute Ischemic Stroke - Pipeline by PhytoHealth Corporation, H1 2016 30
Acute Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H1 2016 31
Acute Ischemic Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H1 2016 32
Acute Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H1 2016 33
Acute Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 34
Assessment by Monotherapy Products, H1 2016 35
Number of Products by Stage and Target, H1 2016 37
Number of Products by Stage and Mechanism of Action, H1 2016 39
Number of Products by Stage and Route of Administration, H1 2016 41
Number of Products by Stage and Molecule Type, H1 2016 43
Acute Ischemic Stroke Therapeutics - Recent Pipeline Updates, H1 2016 87
Acute Ischemic Stroke - Dormant Projects, H1 2016 117
Acute Ischemic Stroke - Dormant Projects (Contd..1), H1 2016 118
Acute Ischemic Stroke - Discontinued Products, H1 2016 119
Acute Ischemic Stroke - Discontinued Products (Contd..1), H1 2016 120